Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
5.38
-0.03 (-0.55%)
At close: Mar 9, 2026, 4:00 PM EDT
5.30
-0.08 (-1.49%)
After-hours: Mar 9, 2026, 6:13 PM EDT
Sagimet Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
14
Market Cap
174.97M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Heron Therapeutics | 154.90M |
| Vaxart | 148.20M |
| Whitehawk Therapeutics | 14.38M |
| Caribou Biosciences | 11.16M |
| Tonix Pharmaceuticals Holding | 10.30M |
| Cartesian Therapeutics | 1.09M |
| SAB Biotherapeutics | 114.70K |
SGMT News
- 6 days ago - Sagimet Biosciences Inc. (SGMT) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript - Seeking Alpha
- 12 days ago - Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Sagimet Announces Positive 52-Week Data from License Partner Ascletis' Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne - GlobeNewsWire
- 5 weeks ago - Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne - PRNewsWire
- 5 weeks ago - Biotech Veteran and Virologist Joins CancerVax as Senior Scientific Advisor - GlobeNewsWire
- 2 months ago - Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference - GlobeNewsWire
- 2 months ago - Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market - Seeking Alpha